V

Vaxcell Bio Therapeutics
KOSDAQ:323990

Watchlist Manager
Vaxcell Bio Therapeutics
KOSDAQ:323990
Watchlist
Price: 9 550 KRW 5.99% Market Closed
Market Cap: 222.1B KRW

Operating Margin

-241.1%
Current
Improving
by 16 975.9%
vs 3-y average of -17 217.1%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-241.1%
=
Operating Income
₩-16.2B
/
Revenue
₩6.7B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-241.1%
=
Operating Income
₩-16.2B
/
Revenue
₩6.7B

Peer Comparison

Country Company Market Cap Operating
Margin
KR
Vaxcell Bio Therapeutics
KOSDAQ:323990
208.8B KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.7B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 96% of companies in Korea
Percentile
4rd
Based on 2 615 companies
4rd percentile
-241.1%
Low
-163 055.6% — -2.2%
Typical Range
-2.2% — 6.8%
High
6.8% — 22 874.8%
Distribution Statistics
Korea
Min -163 055.6%
30th Percentile -2.2%
Median 2.7%
70th Percentile 6.8%
Max 22 874.8%

Vaxcell Bio Therapeutics
Glance View

Market Cap
222.1B KRW
Industry
Biotechnology

Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. The company is headquartered in Hwasun, Jeollanam-Do and currently employs 47 full-time employees. The company went IPO on 2020-09-22. The firm's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The firm sells its products in domestic and overseas markets.

Vaxcell Bio Therapeutics Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-241.1%
=
Operating Income
₩-16.2B
/
Revenue
₩6.7B
What is Vaxcell Bio Therapeutics's current Operating Margin?

The current Operating Margin for Vaxcell Bio Therapeutics is -241.1%, which is above its 3-year median of -17 217.1%.

How has Operating Margin changed over time?

Over the last 2 years, Vaxcell Bio Therapeutics’s Operating Margin has increased from -83 853.2% to -241.1%. During this period, it reached a low of -83 853.2% on Dec 31, 2023 and a high of -241.1% on Oct 30, 2025.

Back to Top